What is CRSP's current stock price?

As of now, CRSP is trading at $56.31, with a daily change of -0.27%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

CRSP Stock Analysis & IQ Rating | CRISPR Therapeutics

CRSP

CRISPR Therapeutics

$56.31

-$0.15 | -0.27%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$78.48

MKT CAP

$5.37B

52W Low

$30.06

VOL

$253.74K

P/E Ratio

N/A

AVG VOL

$2.14M

RSI

50.22

TREND

Sideways

BQ Stock IQ

Login to see CRISPR Therapeutics (CRSP) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

CRSP Target Price

Login to display

Strengths

CRSP Rewards

Earnings are forecast to grow

CRSP Rewards

Upgraded on attractively valued

CRSP Rewards

Trading below its fair value

CRSP Rewards

Outperform the market

CRSP Price Performance

$53.3 (+5.65%)

$64.81 (-13.12%)

$59.59 (-5.50%)

$39.69 (+41.87%)

1year

6month

3month

1month

CRSP Risk Level

CRSP has Fair risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Risks Indicators

Beta greater than 1.0

Fair

LOW

HIGH

CRSP Analysts Opinion

CRSP overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

CRSP Analysts Opinion

CRSP Analysts opinion is positive and also has improved from the past 3 months

CRSP Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

97%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

CRSP Street Sentiment

CRSP Street Sentiment is extremely bullish and have positive views on the near-term outlook

CRSP Performance Sentiment

Sentiments overview associated with CRSP events and the stock performance.

97%

3%

Positive

Negative

33 out of 34
events present

1 out of 34
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$56.56

Resistance
Price

$50.79

Current Price Range

$60.32

Show methods +

Linked to CRSP

IQ

Close Price

Change

VCEL

4.00

37.56

+0.48%

IBRX

3.89

2.11

+0.48%

CLDI

3.50

1.29

-1.53%

BNTX

4.12

95.61

+1.46%

BEAM

4.47

28.08

+1.12%

CRSP Latest Analysis +

Is CRISPR Therapeutics Stock Yesterdays News?. Key PointsCRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval.

Today

$56.31 | -0.27%

Activity

Needham Reiterates CRISPR Therapeutics (CRSP) Buy Recommendation. Fintel reports that on December 23 2025 Needham reiterated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Buy recommendation. Analyst Price Forecast Suggests 41.91% Upside

Today

$56.31 | -0.27%

Rating

Citizens Reiterates CRISPR Therapeutics (CRSP) Market Outperform Recommendation. Fintel reports that on December 23 2025 Citizens reiterated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Market Outperform recommendation. Analyst Price Forecast Suggests 41.91% Upside

Today

$56.31 | -0.27%

Potential

Rating

DYAI: Layers of Commercialization Agreements. By In the weeks following its third quarter 2025 results Dyadic Applied BioSolutions Inc. (NASDAQ:DYAI) announced several new partnerships and partnership expansions that build on its foundation of developing protein solutions for life sciences food and nutrition and bioindustrial applications. The new arrangements were all announced in December and include a development and commercialization agreement signed with BRIG BIO a commercial partnership wi

Mon Dec 22, 2025

$57.91 | +3.67%

Activity

CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood Cancer. CRSP) on Monday provided updates on zugocaptagene geleucel (zugo-cel formerly CTX112) its investigational allogeneic CAR T targeting CD19 in development for autoimmune .Zugo-cel targeting CD19 is in an ongoing Phase 1basket trial in autoimmune rheumatologic diseases.Preliminary clinical data from the Phase 1 study have been encouraging and zugo-cel has been .Also Read: As of the data cut-off on December 17 fou

Mon Dec 22, 2025

$57.91 | +3.67%

Activity

2 Monster Stocks in the Making to Buy and Hold. Key PointsCRISPR Therapeutics and Viking Therapeutics are innovative biotechs with attractive pipelines.

Tue Dec 16, 2025

$56.31 | +0.10%

Potential

Gene Therapies for Cardiomyopathies Market Poised for Rapid Expansion During the Forecast Period (2025-2034) with Advancements in AAV and CRISPR Platforms | DelveInsight. The gene therapies for cardiomyopathies market is poised for strong growth as advancements in genomic medicine accelerate the development of targeted treatments for inherited and acquired cardiac disorders. Additionally emerging candidates such as LX2020 and LX2006 from Lexeo...

Mon Dec 15, 2025

$56.25 | -0.76%

Activity

Potential

Global Gene Therapy Market to Surge to USD 36.55 Billion by 2032 | MarketsandMarkets™. Delray Beach FL Dec. 15 2025 (GLOBE NEWSWIRE) -- Rapid innovation expanding clinical pipelines and rising demand for curative treatments position gene therapy as a transformative growth engine across healthcare markets valued at US$7.21 billion in 2023 stood at US$8.85 billion in 2024 and is projected to advance at a resilient CAGR of 19.4% from 2025 to 2032 culminating in a forecasted valuation of US$36.55 bi

Mon Dec 15, 2025

$56.25 | -0.76%

Activity

Potential

2 Healthcare Stocks to Buy Ahead of the New Year. Key PointsCRISPR Therapeutics could soar on the back of significant pipeline progress next year.

Fri Dec 12, 2025

$56.68 | -2.43%

Activity

Momentum

Potential

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions. Issued on behalf of Avant Technologies Inc. News Commentary – Traditional pharmaceutical strategies are giving ground as breakthrough approvals for gene therapies and mRNA platforms target previously untreatable rare diseases with precision interventions[1]. Healthcare systems integrating AI diagnostic tools now match therapies to individual genetic profiles rather than treating broad populations with reactive symptom

Tue Dec 9, 2025

$57.04 | -0.56%

Activity

FAQ About CRSP Stock Insights

What is CRSP current stock price?

What are CRSP stock strengths?

What is CRSP Risk Level?

What is CRSP market cap and volume?

What is CRSP current Stock IQ?

Should I buy CRSP stock right now?

Is CRSP a Strong Buy right now?

What does a 'Strong Buy' rating mean for CRSP?

What does a 'Strong Sell' rating mean for CRSP?

What factors influence CRSP's Stock IQ?

Explore our CRSP Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored CRSP Stock Strategies
Effective Risk Management

FIND US ON

Receive our CRSP Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

CRSP

CRISPR Therapeutics

Current Price

$56.31

-$0.15 | -0.27%

52W High

$78.48

MKT CAP

$5.37B

52W Low

$30.06

VOL

$253.74K

P/E Ratio

N/A

AVG VOL

$2.14M

RSI

50.22

TREND

Sideways

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

CRSP Rewards

Earnings are forecast to grow

CRSP Rewards

Upgraded on attractively valued

CRSP Rewards

Trading below its fair value

CRSP Rewards

Outperform the market

Linked to CRSP

Symbol

IQ

Close

Change

VCEL

4.00

37.56

+0.48%

IBRX

3.89

2.11

+0.48%

CLDI

3.50

1.29

-1.53%

BNTX

4.12

95.61

+1.46%

BEAM

4.47

28.08

+1.12%

CRSP Price Performance

$53.3 (+5.65%)

$64.81 (-13.12%)

$59.59 (-5.50%)

$39.69 (+41.87%)

1year

6month

3month

1month

CRSP Analysts Opinion

CRSP Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

CRSP Analysts Opinion

CRSP Analysts opinion is positive and also has improved from the past 3 months

CRSP Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

97%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

CRSP Street Sentiment

CRSP Street Sentiment is extremely bullish and have positive views on the near-term outlook

CRSP Risk Level

CRSP has Fair risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Risks Indicators

Beta greater than 1.0

Fair

LOW

HIGH

CRSP Performance Sentiment

Sentiments overview associated with CRSP events and the stock performance.

97%

3%

Positive

Negative

33 out of 34
events present

1 out of 34
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$56.56

Resistance
Price

$50.79

Current Price Range

$60.32

Show methods +

CRSP Stock IQ

Login to unlock CRISPR Therapeutics (CRSP) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

CRSP Latest Analysis

Is CRISPR Therapeutics Stock Yesterdays News?. Key PointsCRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval.

Today

$56.31 | -0.27%

Activity

Needham Reiterates CRISPR Therapeutics (CRSP) Buy Recommendation. Fintel reports that on December 23 2025 Needham reiterated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Buy recommendation. Analyst Price Forecast Suggests 41.91% Upside

Today

$56.31 | -0.27%

Rating

Citizens Reiterates CRISPR Therapeutics (CRSP) Market Outperform Recommendation. Fintel reports that on December 23 2025 Citizens reiterated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Market Outperform recommendation. Analyst Price Forecast Suggests 41.91% Upside

Today

$56.31 | -0.27%

Potential

Rating

DYAI: Layers of Commercialization Agreements. By In the weeks following its third quarter 2025 results Dyadic Applied BioSolutions Inc. (NASDAQ:DYAI) announced several new partnerships and partnership expansions that build on its foundation of developing protein solutions for life sciences food and nutrition and bioindustrial applications. The new arrangements were all announced in December and include a development and commercialization agreement signed with BRIG BIO a commercial partnership wi

Mon Dec 22, 2025

$57.91 | +3.67%

Activity

CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood Cancer. CRSP) on Monday provided updates on zugocaptagene geleucel (zugo-cel formerly CTX112) its investigational allogeneic CAR T targeting CD19 in development for autoimmune .Zugo-cel targeting CD19 is in an ongoing Phase 1basket trial in autoimmune rheumatologic diseases.Preliminary clinical data from the Phase 1 study have been encouraging and zugo-cel has been .Also Read: As of the data cut-off on December 17 fou

Mon Dec 22, 2025

$57.91 | +3.67%

Activity

2 Monster Stocks in the Making to Buy and Hold. Key PointsCRISPR Therapeutics and Viking Therapeutics are innovative biotechs with attractive pipelines.

Tue Dec 16, 2025

$56.31 | +0.10%

Potential

Gene Therapies for Cardiomyopathies Market Poised for Rapid Expansion During the Forecast Period (2025-2034) with Advancements in AAV and CRISPR Platforms | DelveInsight. The gene therapies for cardiomyopathies market is poised for strong growth as advancements in genomic medicine accelerate the development of targeted treatments for inherited and acquired cardiac disorders. Additionally emerging candidates such as LX2020 and LX2006 from Lexeo...

Mon Dec 15, 2025

$56.25 | -0.76%

Activity

Potential

Global Gene Therapy Market to Surge to USD 36.55 Billion by 2032 | MarketsandMarkets™. Delray Beach FL Dec. 15 2025 (GLOBE NEWSWIRE) -- Rapid innovation expanding clinical pipelines and rising demand for curative treatments position gene therapy as a transformative growth engine across healthcare markets valued at US$7.21 billion in 2023 stood at US$8.85 billion in 2024 and is projected to advance at a resilient CAGR of 19.4% from 2025 to 2032 culminating in a forecasted valuation of US$36.55 bi

Mon Dec 15, 2025

$56.25 | -0.76%

Activity

Potential

2 Healthcare Stocks to Buy Ahead of the New Year. Key PointsCRISPR Therapeutics could soar on the back of significant pipeline progress next year.

Fri Dec 12, 2025

$56.68 | -2.43%

Activity

Momentum

Potential

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions. Issued on behalf of Avant Technologies Inc. News Commentary – Traditional pharmaceutical strategies are giving ground as breakthrough approvals for gene therapies and mRNA platforms target previously untreatable rare diseases with precision interventions[1]. Healthcare systems integrating AI diagnostic tools now match therapies to individual genetic profiles rather than treating broad populations with reactive symptom

Tue Dec 9, 2025

$57.04 | -0.56%

Activity

Discover CRSP Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of CRSP. We're here to help you make informed investment decisions today.

FIND US ON

Receive our CRSP Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

CRSP Stock trends

CRSP Stock performance

CRSP Stock analysis

CRSP investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing CRSP

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing CRSP

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

CRSP Stock Analysis & IQ Rating | CRISPR Therapeutics

BQ Stock IQ

CRSP Target Price

CRSP Risk Level

CRSP Analysts Opinion

CRSP Street Sentiment

CRSP Performance Sentiment

Technical Price Levels

Explore our CRSP Stock insights

Receive our CRSP Daily Alerts

CRSP Street Sentiment

CRSP Risk Level

Technical Price Levels

Discover CRSP Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of CRSP. We're here to help you make informed investment decisions today.

Receive our CRSP Daily Alerts

CRSP Alerts